Department of Diagnostic and Intervention, Umeå Universitet, Umeå, Sweden; Wallenberg Centre for Molecular Medicine, Umeå Universitet, Umeå, Sweden.
Department of Diagnostic and Intervention, Umeå Universitet, Umeå, Sweden; Wallenberg Centre for Molecular Medicine, Umeå Universitet, Umeå, Sweden.
Biochem Pharmacol. 2024 Nov;229:116492. doi: 10.1016/j.bcp.2024.116492. Epub 2024 Aug 15.
Pancreatic adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer deaths by 2030 and this is mostly due to therapy failure. Limited treatment options and resistance to standard-of-care (SoC) therapies makes PDAC one of the cancer types with poorest prognosis and survival rates [1,2]. Pancreatic tumors are renowned for their poor response to therapeutic interventions including targeted therapies, chemotherapy and radiotherapy. Herein, we review hallmarks of therapy resistance in PDAC and current strategies aiming to tackle escape mechanisms and to re-sensitize cancer cells to therapy. We will further provide insights on recent advances in the field of drug discovery, nanomedicine, and disease models that are setting the ground for future research.
胰腺癌（PDAC）预计将成为 2030 年癌症死亡的第二大主要原因，这主要是由于治疗失败。治疗选择有限以及对标准治疗（SoC）疗法的耐药性使得 PDAC 成为预后和生存率最差的癌症类型之一 [1,2]。胰腺肿瘤以对治疗干预（包括靶向治疗、化疗和放疗）的反应差而闻名。在此，我们回顾了 PDAC 中治疗耐药的特征以及当前旨在解决逃逸机制和使癌细胞重新对治疗敏感的策略。我们将进一步提供药物发现、纳米医学和疾病模型领域的最新进展的见解，为未来的研究奠定基础。
